Within this seven-gene panel, CD27 is a target for immune checkpoint inhibitors (ICIs) [16], and anti-CD27 mAb is being tested as an adjuvant immunotherapy in phase I/II clinical trials for multiple tumor types with promising results [17,18]. The gene discussed is CD27; the disease is neoplasm.